Latest Commercialization News

5E Advanced Materials is raising up to $36 million through a stock offering to fund the development of its Fort Cady boron and lithium project in California. The capital raise comes amid ongoing concerns about the company’s ability to continue as a going concern without further financing.

The Tennant Creek Copper Alliance, comprising CuFe, Emmerson Resources, and Tennant Minerals, has secured $600,000 in government grants matched by the companies to fund a feasibility study for a shared critical minerals processing facility in Tennant Creek.

The Tennant Creek Copper Alliance has won $600,000 in government grants, matched by the partners, to fund a feasibility study for a shared critical minerals processing facility. This initiative aims to unlock the economic potential of copper, gold, silver, and bismuth resources in the Northern Territory.

Aspermont Limited reported a $1.49 million net cash outflow in Q1 FY26 but maintains its forecast to become cash generative by Q3, supported by strong trading performance and strategic progress.

GreenTech Metals has completed a transformative acquisition of a majority interest in the Munni Munni platinum group elements project in Western Australia, with drilling underway to verify and expand historic resources.

Bellavista Resources Ltd has agreed to acquire up to 80% of the Pickle Crow Gold Project in Ontario, Canada, adding a 2.8 million ounce inferred gold resource at 7.2g/t to its portfolio. The company is raising A$25 million to fund aggressive exploration and development activities.

Estrella Resources has entered a $2 million underwriting agreement to support the exercise of its listed options, ensuring capital inflow ahead of the December expiry.

Actinogen Medical has raised approximately $17 million through a share placement and purchase plan to fund the completion of its pivotal XanaMIA Alzheimer’s trial following encouraging interim results.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

Axel REE Limited's latest magnesium sulphate leach tests at the Paraíso target confirm robust rare earth grades and a magnet-rich basket, underpinning a modular in-situ leach development at the Caladão Project in Brazil.

Corporate Travel Management's founder Jamie Pherous retires, handing over leadership to Ana Pedersen as the company navigates accounting challenges and aims to relist on the ASX.